๐Ÿ”ฌ Expanding our integrated capabilities in autoimmune research
September 3, 2025

At Pharmidex, we are proud to offer a comprehensive preclinical platform for autoimmune disease research.


Using in vivo EAE models, we combine:

 โœ”๏ธ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression

 โœ”๏ธ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs

 โœ”๏ธ Pharmacological intervention studies, including established treatments


This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation.


By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects.


๐Ÿ‘‰ Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.

Expanding our integrated capabilities in autoimmune research
October 20, 2025
๐ŸŒŸ Exciting Announcement from Pharmidex ! ๐ŸŒŸ We’re delighted to share that our Head of Business Development, Martin Barrett , will be attending the upcoming conference: ELRIG Drug Discovery 2025 (21–22 October 2025 | Liverpool, UK). Martin will be eager to connect with fellow life-sciences innovators, exchange ideas and explore new collaborations and opportunities to accelerate drug discovery and development. If you’ll be at the event, we’d love to invite you to meet Martin for a chat about how we can work together. See you in Liverpool!
GMP Symposium
October 13, 2025
Pharmidex will be attending the GMP 37th Symposium
More Posts